jnj-18038683
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00566202)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 7 (5-HT7) receptorANTAGONIST
HTR7 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Clc1ccc(-c2nn(Cc3ccccc3)c3c2CCNCC3)cc1- Mol. weight
- 337.85 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297293 ↗
- ChEMBLCHEMBL4205783 ↗
Also known as
- 3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydro-1-(phenylmethyl)pyrazolo(3,4-d)azepine 2-hydroxy-1,2,3-propanetricarboxylate
- jnj-18038683
- jnj-18038683
- jnj-18038683
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03633357 | N/A | Aug 16, 2018 | University of London |
| NCT02466685 | Phase 2 | Sep 1, 2015 | Johnson and Johnson, Northwestern University |
| NCT00566202 | Phase 2 | Dec 1, 2007 | Johnson and Johnson |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 1 | 1 | 2007 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1